Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group

S. Sasse, H. Goergen, A. Plütschow, B. Böll, DA. Eichenauer, M. Fuchs, K. Behringer, JM. Zijlstra, R. Greil, J. Markova, MS. Topp, J. Meissner, A. Neubauer, C. Baues, A. Engert, P. Borchmann, B. von Tresckow,

. 2018 ; 36 (25) : 2603-2611. [pub] 20180710

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Purpose The prognostic effect of isolated infradiaphragmatic involvement in Hodgkin lymphoma (HL) is controversial, and there are little data about patients treated with current therapies. Therefore, we performed a risk factor analysis to focus on isolated nodal infradiaphragmatic disease in patients treated within the German Hodgkin Study Group trials HD13 (clinical trial information: ISRCTN63474366) and HD14 (clinical trial information: ISRCTN04761296) for early-stage HL. Patients and Methods Characteristics and outcomes of patients who had infradiaphragmatic HL were compared with patients who had supradiaphragmatic disease. Progression-free survival (PFS) and overall survival (OS) were estimated according to Kaplan-Meier methods and were compared between groups using the log-rank test and Cox proportional hazards regression, which was also applied for multivariable analyses that adjusted for relevant baseline characteristics. Results Of 2,903 qualified patients, 223 (7.7%) were diagnosed with isolated nodal infradiaphragmatic disease. In general, these patients were older, had a poorer performance status, were more often male, and had the nodular sclerosis subtype less often than those with supradiaphragmatic disease. After a median follow-up time of 51 months, PFS and OS were significantly worse in patients with infradiaphragmatic disease (5-year PFS and OS, 80.1% and 91.5% v 91.2% and 97.6% in patients with supradiaphragmatic disease; each P < .001). In multivariable analyses, infradiaphragmatic HL remained a significant risk factor in terms of PFS (hazard ratio [HR], 1.5; 95% CI, 1.04 to 2.2; P = .03) and OS (HR, 2.0; 95% CI, 1.2 to 3.5; P = .01). However, inferior PFS and OS could not be observed among those patients treated with the more intensive chemotherapy (two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD] in HD13, and two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPPescalated] plus two cycles of ABVD in HD14; all patients received 30 Gy of involved-field radiotherapy). Conclusion Early-stage HL that presents with infradiaphragmatic disease only represents a distinct patient group with an inferior outcome. However, this adverse outcome can be outweighed by appropriate combined modality treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035132
003      
CZ-PrNML
005      
20191008110816.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2018.78.7192 $2 doi
035    __
$a (PubMed)29989855
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sasse, Stephanie $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
245    10
$a Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group / $c S. Sasse, H. Goergen, A. Plütschow, B. Böll, DA. Eichenauer, M. Fuchs, K. Behringer, JM. Zijlstra, R. Greil, J. Markova, MS. Topp, J. Meissner, A. Neubauer, C. Baues, A. Engert, P. Borchmann, B. von Tresckow,
520    9_
$a Purpose The prognostic effect of isolated infradiaphragmatic involvement in Hodgkin lymphoma (HL) is controversial, and there are little data about patients treated with current therapies. Therefore, we performed a risk factor analysis to focus on isolated nodal infradiaphragmatic disease in patients treated within the German Hodgkin Study Group trials HD13 (clinical trial information: ISRCTN63474366) and HD14 (clinical trial information: ISRCTN04761296) for early-stage HL. Patients and Methods Characteristics and outcomes of patients who had infradiaphragmatic HL were compared with patients who had supradiaphragmatic disease. Progression-free survival (PFS) and overall survival (OS) were estimated according to Kaplan-Meier methods and were compared between groups using the log-rank test and Cox proportional hazards regression, which was also applied for multivariable analyses that adjusted for relevant baseline characteristics. Results Of 2,903 qualified patients, 223 (7.7%) were diagnosed with isolated nodal infradiaphragmatic disease. In general, these patients were older, had a poorer performance status, were more often male, and had the nodular sclerosis subtype less often than those with supradiaphragmatic disease. After a median follow-up time of 51 months, PFS and OS were significantly worse in patients with infradiaphragmatic disease (5-year PFS and OS, 80.1% and 91.5% v 91.2% and 97.6% in patients with supradiaphragmatic disease; each P < .001). In multivariable analyses, infradiaphragmatic HL remained a significant risk factor in terms of PFS (hazard ratio [HR], 1.5; 95% CI, 1.04 to 2.2; P = .03) and OS (HR, 2.0; 95% CI, 1.2 to 3.5; P = .01). However, inferior PFS and OS could not be observed among those patients treated with the more intensive chemotherapy (two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD] in HD13, and two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPPescalated] plus two cycles of ABVD in HD14; all patients received 30 Gy of involved-field radiotherapy). Conclusion Early-stage HL that presents with infradiaphragmatic disease only represents a distinct patient group with an inferior outcome. However, this adverse outcome can be outweighed by appropriate combined modality treatment.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bleomycin $x aplikace a dávkování $x škodlivé účinky $7 D001761
650    _2
$a chemoradioterapie $x metody $7 D059248
650    _2
$a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $7 D003520
650    _2
$a dakarbazin $x aplikace a dávkování $x škodlivé účinky $7 D003606
650    _2
$a doxorubicin $x aplikace a dávkování $x škodlivé účinky $7 D004317
650    _2
$a etoposid $x aplikace a dávkování $x škodlivé účinky $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a Hodgkinova nemoc $x mortalita $x patologie $x terapie $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lymfatické metastázy $x patologie $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prednison $x aplikace a dávkování $x škodlivé účinky $7 D011241
650    _2
$a prokarbazin $x aplikace a dávkování $x škodlivé účinky $7 D011344
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x aplikace a dávkování $x škodlivé účinky $7 D014750
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Goergen, Helen $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Plütschow, Annette $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Böll, Boris $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Eichenauer, Dennis A $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Fuchs, Michael $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Behringer, Karolin $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Zijlstra, Joseé M $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Greil, Richard $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Markova, Jana $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Topp, Max S $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Meissner, Julia $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Neubauer, Andreas $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Baues, Christian $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Engert, Andreas $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Borchmann, Peter $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a von Tresckow, Bastian $u Stephanie Sasse, Helen Goergen, Annette Plütschow, Boris Böll, Dennis A. Eichenauer, Michael Fuchs, Karolin Behringer, Christian Baues, Andreas Engert, Peter Borchmann, and Bastian von Tresckow, University Hospital of Cologne, Cologne; Max S. Topp, University Hospital of Würzburg, Würzburg; Julia Meissner, University of Heidelberg, Heidelberg; Andreas Neubauer, Philipps University, Marburg, Germany; Joseé M. Zijlstra, VU University Medical Center, Amsterdam, the Netherlands; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute and Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; and Jana Markova, Charles University in Prague and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic.
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 36, č. 25 (2018), s. 2603-2611
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29989855 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191008111232 $b ABA008
999    __
$a ok $b bmc $g 1451792 $s 1073682
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 36 $c 25 $d 2603-2611 $e 20180710 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...